MacroGenics Inc. — ZYNYZ (retifanlimab-dlwr) - (POD1UM-304) · Non-small cell lung cancer (NSCLC).
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (10/22/25) through T+5. Run-up high $3.43 on 3/11/26, low $1.33 on 12/15/25 (T-120 to T-1). FDA decision 4/8/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-04-08
OutcomeCRL
Drug / candidateZYNYZ (retifanlimab-dlwr) - (POD1UM-304)